Improve patients' lives by timely providing them with

quality and affordable protein therapeutics

Honor
  • 2021
    Red Cross Society of China Fujian Branch "Honor Certificate for Charity"
  • 2021
    National Worker Pioneer (Henlius HLX01 - Project Core Team)
  • 2021
    Global Health & Pharma Magazine "Most Innovative Global Biopharmaceutical Company 2021"
  • 2020
    Shanghai Model Group
  • 2020
    5th Social Value Co-creation Outstanding Award
  • 2020
    Gelonghui "2020 The Best Listing Company - Best Information Disclosure Award"
  • 2020
    CIPRA "The 16th China Global Awards for Excellence in Public Relations Social Responsibility Bronze Award"
  • 2020
    eMedClub PharmaBIGStar - "Top 50 Most Innovative Companies of Chinese Biomedicine in 2020"
  • 2020
    JRJ.COM "Jinzhi Award - The Most Valued Top 10 in Biopharmaceutical Industry"
  • 2020
    CNPIIC "China Innovation New Power in Pharmaceutical Industry"
  • 2020

    Changchun Award "2020 Innovative Pharmaceutical Enterprise"

  • 2020
    China Pharmaceutical Brand with Greatest Growth Potential - 汉利康® HLX01 Rituximab Injection
  • 2020
    2019 China Biopharmaceutical Company Top 20
  • 2020
    EBC Awards "The Most Influential Enterprise in Biopharmaceutical Industry"
  • 2020
    China Youth "2019 PR Influence Top 20 Startup in Pharmaceutical Industry"
  • 2019
    ZJ Science City "Outstanding Listed Company"
  • 2019
    The 4th Jin Gang Gu "The Most Valuable Pharmaceutical Enterprise"
  • 2019
    The 8th Charity Festival  "Innovative CSR Activity Award"
  • 2019

    Sina Medical - Wisdom Growing Forum "The Most Valued Biopharmaceutical Enterprise"

  • 2019

    Sina Medical - Wisdom Growing Forum "The Best Charity Event in BioPharm Industry"

  • 2019
    Vcbeat Net "Future Healthcare VB 100"
  • 2019
    ONE FOSUN CSR Week "Special CSR Activity - Understanding Lymphoma: A Medical Education Charity Event"
  • 2019

    Global Generics & Biosimilars Awards  "Company of the Year,Asia Pacific - Finalist"

  • 2019
    Global Generics & Biosimilars Awards 2019 "Biosimilar Initiative of the Year - 汉利康®
  • 2019

    ZCCS "The Most Innovative Award"

  • 2019
    Equal Ocean "China Healthcare Industry Award - the Best Innovative Biopharmaceutical Enterprise"
  • 2019
    Frost & Sullivan  "China New Economy Award - Excellence in Innovation"
  • 2019
    MENET, Medicine Economic Reporter "Top 20 Biopharmaceutical Company in China"
  • 2019

    The 8th China Finance Summit "The Most Innovative Enterprise"

  • 2019

    Trade Union of Xuhui District, Science and Technology Commission of Xuhui District "2019 Xuhui District Innovation Centre for Science & Technology Contest Finalist"

  • 2019
    China Financial Market "Excellent Biopharmaceutical Enterprise" 
  • 2019
    Forbes China "The Most Innovative Companies in China"
  • 2019
    JRJ.com "Future Company of BioPharm Industry"
  • 2019
    Shanghai Worker Pioneer HLX01 Core Project Team
  • 2018
    Sina Medical "The Most Innovative Enterprise in Pharmaceutical Industry in 2018 China"
  • 2018
    Social Responsibility Conference "2018 Branding Award"
  • 2018
    Chinese Pharmaceutical Association "The Fast-growing Pharmaceutical Enterprise of Science and Technology Innovation in 2018"
  • 2018

    Ernst & Young "The Most Promising Enterprises in China"

  • 2018
     Vcbeat Net "Top of 2018 Future Medicine 100"
  • 2018

    Venture 50 "China Top 50 Investments for Value "

  • 2018

    China Business Journal "The Most Innovative Enterprise in Health Industry"

  • 2018

    The 7th China Finance Summit "The Most Innovative Enterprise"

  • 2018
    China Entrepreneur "Future Stars"
  • 2018

    Science and Technology Innovation Award for Songjiang Manufacturing Facility

  • 2018

    China Healthcare Consulting Group(CHC)-CITIC Securities "2017 Top Venture in Medical and Health"

  • 2018

    Life Science & Healthcare Unicorn Enterprise in Pudong New Area, Shanghai

  • 2018

    Innovative Startup Top 20 in Pudong New Area

  • 2018

    Haoyue Capital "Annual Best Venture Case in Biopharm "

  • 2018

    IMAPAC "Bioprocessing Innovations in Single-use Manufacturing in China"

  • 2018

    BioPharma "Asia Biotech of 2017"

  • 2017
    Life Science & Healthcare Unicorn Enterprise in China
  • 2017

    Deloitte Touche Tohmatsu "2017 Future Star in the China Pharma Industry"

  • 2017

    IMAPAC "Leading Innovations in Cutting-edge Technologies for Novel mAb Development & Production"

  • 2017

    IMAPAC "Best Bioprocessing Excellence in China"

Global Generics & Biosimilars Awards 2019
"Biosimilar Initiative of the Year - 汉利康®"

Generics Bulletin & IQVIA


The Most Innovative Companies in China

Forbes China

Asia Biotech of 2017

BioPharma

Bioprocessing Innovations in Single-use Manufacturing in China
Development & Production

IMAPAC

Excellent Biopharmaceutical Enterprise

China Financial Market

R&D Project
  • 2020
    National Major R&D Program "Public Security All-risk Prevention & Control and Emergency Technical Equipment" —— COVID-19 Project
  • 2020

    Xuhui Enterprise Technology Research Center

  • 2020
    Postdoctoral Education Station in Pudong New Area
  • 2020
    Shanghai Major Construction Projects and Shanghai Strategic Emerging Industry Projects (Songjiang Manufacturing Facility)
  • 2020

    National Technology Transformation Project (Songjiang Manufacturing Facility)

  • 2019
    National Science and Technology Major Project in the 13th Five-year Plan of China —— Major New Drug Research & Development Project
  • 2018
    Shanghai Anti-tumour Biologic Medicine Engineering and Technology Research Centre
  • 2018

    Research & Development Enterprise in Pudong New Area

  • 2018

    National Science and Technology Major Project in the 13th Five-year Plan of China —— Major New Drug Research & Development Project

  • 2018

    Shanghai Technology Giant Enterprise

  • 2018

    Shanghai Industry Transformation and Upgrade Program —— Projects to Build a Robust Foundation for Industrial Development

  • 2017

    Specialised & Innovative SME

  • 2016
    High and New Technology Enterprises
  • 2015
    Shanghai Industry Transformation and Upgrade Program (Xuhui Manufacturing Facility)
  • 2012

    National Science and Technology Major Project in the 12th Five-year Plan of China —— Major New Drug Research & Development Project

  • 2011

    National Science and Technology Major Project in the 12th Five-year Plan of China —— Major New Drug Research & Development Project